Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pramipexole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.97 |
| ▸ | HRH2 | P25021 | 2/20 | 0.95 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.95 |
| ▸ | HTR1A | P08908 | 1/20 | 0.95 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.95 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.95 |
| ▸ | HTR1B | P28222 | 1/20 | 0.95 |
| ▸ | HTR2A | P28223 | 1/20 | 0.95 |
| ▸ | HTR7 | P34969 | 1/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.95 |
| ▸ | HRH1 | P35367 | 1/20 | 0.95 |
| ▸ | HTR2B | P41595 | 1/20 | 0.95 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.95 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.95 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.54 |
| ▸ | SCN4A | P35499 | 4/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pramipexole SCHEMBL22165339 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Pramipexole SCHEMBL28361114 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Pramipexole SCHEMBL28345162 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Pramipexole SCHEMBL2048695 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Pramipexole SCHEMBL153875 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Pramipexole SCHEMBL743891 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Dexpramipexole SCHEMBL2289178 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Pramipexole SCHEMBL28506481 | 1.00 | DRD3 (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Dexpramipexole SCHEMBL910147 | 0.99 | ADRA2A (1.00) | DRD3DRD2DRD4ADRA2AHRH2 | |
| Pramipexole SCHEMBL20524815 | 0.99 | DRD3 (0.97) | DRD3DRD2DRD4ADRA2AHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104146979-A | Pramipexole dihydrochloride sustained release tablet and preparation method thereof | SHANGHAI SUNTECH PHARMACEUTICAL CO LTD | 2014-11-19 | — | — | CN | claimed |
| EP-1093369-B1 | AGENT WITH AN ANTIDEPRESSIVE EFFECT COMPRISING PRAMIPEXOLE AND SERTRALINE | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-11-27 | — | — | EP | claimed |
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4729123-A2 | COMPOSITIONS COMPRISING PRAMIPEXOLE AND A 5HT3 ANTAGONIST FOR USE IN TREATING DEPRESSION | Alto Neuroscience, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260069573-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3615024-B1 | COMPOSITIONS COMPRISING PRAMIPEXOLE AND A 5HT3 ANTAGONIST FOR USE IN TREATING DEPRESSION | ALTO NEUROSCIENCE INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12521374-B1 | Combination therapy for a dopamine agonist | ALTO NEUROSCIENCE, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| CN-118681024-A | Compositions and methods for treating depression | 才思治疗公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-110719778-B | Compositions and methods for treating depression | 才思治疗公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11547700-B2 | Compositions and methods for treating synucleinopathies | CHASE THERAPEUTICS CORPORATION (US) | 2023-01-10 | — | — | US | disclosed |
| CN-110662537-A | Compositions and methods for treating synucleinopathies | 才思治疗公司 | 2020-01-07 | — | — | CN | disclosed |
| WO-2018200387-A1 | COMPOSITIONS AND METHOD FOR TREATING DEPRESSION | CHASE THERAPEUTICS CORPORATION (US) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018191408-A1 | PHARMACEUTICAL COMBINATION AND ITS USE FOR TREATING SYNUCLEINOPATHIES | CHASE THERAPEUTICS CORPORATION (US) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018183192-A1 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | CHASE THERAPEUTICS CORPORATION (US) | 2018-10-04 | — | — | WO | disclosed |
| CN-104367562-A | Pramipexole dihydrochloride slow-release tablets and preparation method thereof | SHANGHAI SUNTECH PHARMACEUTICAL CO LTD | 2015-02-25 | — | — | CN | disclosed |
| CN-104146979-A | Pramipexole dihydrochloride sustained release tablet and preparation method thereof | SHANGHAI SUNTECH PHARMACEUTICAL CO LTD | 2014-11-19 | — | — | CN | disclosed |
| EP-2051971-A1 | PROCESS FOR THE PREPARATION OF PRAMIPEXOLE BASE AND/OR ITS SALTS | INSTYTUT FARMACEUTYCZNY (PL) | 2009-04-29 | — | — | EP | disclosed |
| US-20090105483-A1 | PROCESS FOR THE PREPARATION OF PRAMIPEXOLE BASE AND/OR ITS SALTS | INSTYTUT FARMACEUTYCZNY (PL) | 2009-04-23 | — | — | US | disclosed |
| WO-2007075095-A1 | PROCESS FOR THE PREPARATION OF PRAMIPEXOLE BASE AND/OR ITS SALTS | INSTYTUT FARMACEUTYCZNY (PL) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | SLC6A3, SLC6A4, HTR4 | DRD3 7/4885DRD2 10/4885DRD4 20/4885 |
| US-20260069573-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | SLC6A3, SLC6A4, HTR4 | DRD3 10/4885DRD2 11/4885DRD4 20/4885 |
| US-20090105483-A1 | PROCESS FOR THE PREPARATION OF PRAMIPEXOLE BASE AND/OR ITS SALTS | DPP4, TPMT, DNPEP | DRD3 2510/4885DRD2 1256/4885DRD4 684/4885 |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | HTR1D, PARK7, HTR3A | DRD3 59/4885DRD2 58/4885DRD4 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.